CSIMarket
 
Hookipa Pharma inc   (HOOK)
Other Ticker:  
 
 
Price: $0.7190 $0.02 2.334%
Day's High: $0.7343 Week Perf: 0.86 %
Day's Low: $ 0.70 30 Day Perf: 7.97 %
Volume (M): 131 52 Wk High: $ 2.05
Volume (M$): $ 94 52 Wk Avg: $0.78
Open: $0.70 52 Wk Low: $0.41



 Market Capitalization (Millions $) 68
 Shares Outstanding (Millions) 95
 Employees -
 Revenues (TTM) (Millions $) 20
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 4

Hookipa Pharma Inc
Hookipa Pharma Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immunotherapeutics for cancer and infectious diseases. The company is known for its proprietary technology platform, Vaxwave', which is designed to stimulate both the innate and adaptive immune systems. Hookipa Pharma's goal is to create a new class of immunotherapeutics that are safer and more effective than traditional approaches. The company is headquartered in New York, United States.


   Company Address: 350 Fifth Avenue, 72nd Floor, Suite 7240 New York 10118 NY
   Company Phone Number: 890 63 60   Stock Exchange / Ticker: NASDAQ HOOK
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Hookipa Pharma Inc

Hookipa Pharma Inc Faces Setback as Fourth Quarter Revenue Dips Slightly

Hookipa Pharma Inc, a biopharmaceutical company that specializes in immunotherapeutics, has seen a drop in its shares over the course of March. The share price has decreased by -5.97% during this period, bringing it to a total decrease of 10.89% in the past 90 days. Currently, Hookipa Pharma Inc shares are trading on the NASDAQ at -6.8% below its 52 week average.
For the financial fourth quarter of 2023, Hookipa Pharma Inc experienced losses of $-0.16 per share, compared to $-0.11 per share the previous year. However, there was an improvement in earnings per share (EPS), which increased from $-0.17 per share in the prior reporting period. Revenue also saw a decline of -5.378% to $7.41 million, compared to $7.83 million in the same reporting period a year ago. However, revenue did increase sequentially by 7.864% from $6.87 million.

Partnership

HOOKIPA Aims for Groundbreaking Progress with HPV16+ and Infectious Diseases Focused Developments

Published Mon, Jan 29 2024 1:01 PM UTC

HOOKIPA Pharma Inc., a pioneer in biopharmaceutical immunotherapeutics based on its innovative arenavirus platform, has declared two decisive areas of focus for its resources, with high hopes to make significant strides in diverse medical fields.Firstly, the company has selected the clinical development of the HB-200 program as a high-priority task. HOOKIPA intends to run a ...

Shares

HOOKIPA Pharma Strengthens Position with $21.25 Million Equity Investment from Gilead Sciences

Published Thu, Dec 21 2023 12:01 PM UTC



In a recent press release, HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA) has announced that it has secured a significant financial boost from Gilead Sciences (Gilead). With the purchase of 15 million shares at $1.4167 per share, Gilead has invested approximately $21.25 million in HOOKIPA Pharma. This strategic equity investment reflects the growing confidence in HOOK...

Clinical Study

HOOKIPA Pharma's Revolutionary HIV Therapeutic Vaccine, HB-500, Receives FDA Clearance, Paving the Way for a New Era of Treatment

Published Mon, Nov 20 2023 12:01 PM UTC



HOOKIPA Pharma Inc., a renowned biopharmaceutical company known for its innovative immunotherapeutics, has recently announced a significant breakthrough - the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). This clearance allows HOOKIPA to advance its novel arenaviral therapeutic vaccine, HB-500, for the t...

Hookipa Pharma Inc

Groundbreaking Insights Unveiled: Hookipa Pharma Inc Surpasses Expectations in Fiscal Year Ending September 30, 2023



Hookipa Pharma Inc, a biotechnology company, recently released its financial results for the third quarter of 2023. The results indicate a significant improvement in earnings per share (EPS) and a substantial increase in revenue. However, amidst the positive trends, the company continues to face a net deficit and challenges in accounts receivable management. This article will examine the implications of these financial results and provide insights into how they may impact the future of Hookipa Pharma Inc.
Positive Earnings Per Share (EPS) Improvement:
Hookipa Pharma Inc achieved a noteworthy reduction in losses per share, reporting a decrease from $-0.25 in the previous year to $-0.17 in the third quarter of 2023. This improvement demonstrates the company's ability to manage costs more efficiently and indicates a positive trend for investors. Moreover, in comparison to the previous quarter, the EPS improved from $-0.22 per share to $-0.17 per share, indicating steady progress.






 

Hookipa Pharma Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Hookipa Pharma Inc does not provide revenue guidance.

Earnings Outlook
Hookipa Pharma inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com